Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
On 23 June 20222, BioNTech announced that BNT211, its combination chimeric antigen receptor (CAR) T cell therapy plus RNA vaccine booster targeting the tight-junction protein claudin-6 had been awarded Priority Medicine (PRIME) status by the European Medicines Agency for testing in patients with relapsed or treatment refractory testicular cancer. Instituted in March 2016 “to enhance support for the development of medicines that target an unmet medical need,” PRIME provides an accelerated assessment timeline and expert support to overcome regulatory hurdles throughout a clinical trial. The first therapies approved for PRIME were two CAR T cell therapies: Kymriah (Novartis) for B cell acute lymphocytic leukemia; and Yescarta (Kite Pharma/Gilead) for diffuse large B cell lymphoma.